EGFR Positive Lung Cancer UK

Name

EGFR Positive Lung Cancer UK

Legal name

EGFR Positive UK

Website

https://egfrpositive.org.uk

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

EGFR Positive UK is the only UK charity dedicated to EGFR-mutated lung cancer, providing free peer support, information, advocacy, and research resources for affected patients and families, funded primarily through community donations and fundraising.

Ownership category

akta.pro rank

Product category

Patient Advocacy Charity / Cancer Support Services

NAICS

Voluntary Health Organizations (813212), Other Individual and Family Services (624190)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Lung cancer support
• Patient advocacy charity
• EGFR mutation information
• Cancer community support
• Nonprofit patient services

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Donations and Fundraising: EGFR Positive UK is a patient-driven charity funded primarily through donations and community fundraising. In the financial year 2024-25, total income was £89,937, with £72,178 (81%) coming from fundraisers and Gift Aid. The charity uses JustGiving for its crowdfunding platform and easyfundraising to partner with over 7,000 retail brands who donate a percentage of consumer spend.

Distribution channels5 records

Marketing channels9 records

Core offering

EGFR Positive UK is a patient-driven UK charity that delivers free peer support, clinical information, advocacy and awareness services to people living with EGFR-mutated non-small cell lung cancer and their families. Its core offerings include a private Facebook support community with over 750 members, monthly online and 15 regional in-person meetups, expert-led information resources (EGFR Good Practice Guide, treatment options, clinical trials listings), the Breathe Strong podcast, annual one-day patient conferences, and policy advocacy with NICE, the NHS and other decision-makers.

Differentiator

Problem solved

Functional benefit

Brands

• Breathe Strong: A podcast built around open, natural conversation for EGFR+ lung cancer patients, families, caregivers and healthcare professionals, exploring topics including diagnosis, mental health, travel, and relationships.

Products and services

• Patient Support Community (Facebook group + monthly meetups)
• Breathe Strong Podcast
• EGFR+ UK One-Day Patient Conferences
• Adjuvant Osimertinib Follow-up Care Position Statement

Quantifiable outcome

• 83.3% of survey respondents reported significant scanxiety and above-normal anxiety/depression, informing advocacy for mental health support
• +7 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• HASAG (Mesothelioma and Lung Cancer Charity)coreStrategic or Co-development Partner · 1 February 2026HASAG partnered with EGFR+ UK to co-create the 'Breathe Strong' podcast hosted by nurse specialist Rachel Thomas. The podcast brings together EGFR+ UK and HASAG community members (patients, families, caregivers, and healthcare professionals) for honest conversations about living with lung cancer. EGFR+ UK and HASAG jointly participate in podcast production, with community members from both groups sharing experiences in episodes.
• Lung Cancer Europe (LuCE)coreStrategic or Co-development Partner · 15 August 2024EGFR+ UK became a member of Lung Cancer Europe (LuCE), joining a community of organisations dedicated to improving lung cancer care across Europe. EGFR+ UK attended its first LuCE AGM in Berlin (April 2025) as a member. LuCE endorsed the 'All You Need Is Lungs' campaign. EGFR+ UK contributes to European advocacy, shares best practices (MRI protocols, mental health, exercise resources), and participates in the Access to Treatment Atlas initiative mapping lung cancer treatments by country.
• InsurancewithminorGTM or Marketing Partner · 1 July 2024Insurancewith has partnered with EGFR+ UK to provide bespoke, competitively priced travel insurance for EGFR+ lung cancer patients. EGFR+ UK works with the underwriters to deepen understanding of EGFR+ disease, its treatment, and side effects. This partnership has already resulted in reduced policy premiums for patients with historic brain metastases. EGFR+ UK hosted Fiona Macrae (founder) for an 'Ask the Expert' session on travel insurance.
• AstraZeneca (and The House of Commons)minorGTM or Marketing Partner · 24 January 2024EGFR+ UK attended a parliamentary event at the House of Commons organised by AstraZeneca and The House of Commons, focusing on genomics and biomarker testing in cancer diagnosis and treatment. Chair Angela Terry delivered a patient voice speech. The event brought together MPs, oncologists, and healthcare professionals to discuss precision medicine and personalised care across the UK.
• ALK+ UKcoreStrategic or Co-development Partner · 1 November 2023EGFR+ UK collaborates with ALK+ UK (another mutation-driven lung cancer charity) on awareness campaigns including 'All You Need Is Lungs' (challenging lung cancer stereotypes and stigma) and 'See Through the Symptoms' (targeting primary care professionals). Both charities co-developed these campaigns. EGFR+ UK also partners with ALK+ UK on joint research into wellbeing of patients with mutation-driven lung cancer, in partnership with the Ruth Strauss Foundation and the Open University. Debra Montague, Chair of ALK+ UK, provided mentorship to EGFR+ UK Chair Angela Terry.
• The Ruth Strauss FoundationcoreStrategic or Co-development Partner · 1 November 2023The Ruth Strauss Foundation collaborates with EGFR+ UK and ALK+ UK on joint campaigns including 'All You Need Is Lungs' and 'See Through the Symptoms'. The foundation is also a partner in EGFR+ UK's research into patient wellbeing, working alongside the Open University to explore developing online support resources for mutation-driven lung cancer patients.
• easyfundraisingminorGTM or Marketing Partner · 1 November 2023EGFR Positive UK joined easyfundraising, the UK's largest charity shopping site, to raise funds. The platform partners with over 7,000 brands who donate a percentage of consumer spend to EGFR+ UK at no additional cost. Supporters can sign up, download a browser extension, and generate free donations when shopping with brands including Apple, John Lewis, Boots, ASOS, M&S, and JustEat.
• Open UniversityminorStrategic or Co-development PartnerEGFR+ UK partnered with the Open University, alongside ALK+ UK and the Ruth Strauss Foundation, to conduct research into the wellbeing of patients with mutation-driven lung cancer. The partnership aims to identify patient support needs and explore the development of an online support program or resource dedicated to lung cancer patients.
• University of SouthamptonminorStrategic or Co-development PartnerEGFR+ UK is conducting research in partnership with the University of Southampton investigating treatment resistance mechanisms in EGFR+ lung cancer. The charity also partners with Southampton researchers on studies into patient wellbeing and quality of life, including work presented at BTOG 2024 by Lynn Calman's group.
• University of Bristol (RAMON study)minorStrategic or Co-development PartnerEGFR+ UK promotes the RAMON study (investigating radical treatment for metastatic lung cancer) to its community, connecting patients with clinical trial opportunities. The charity facilitates patient recruitment by sharing information about this Phase 3 study exploring surgery, radiotherapy, or ablation alongside systemic treatment.

Scale indicators12 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Asthma + Lung UK: UK-wide respiratory charity (formerly British Lung Foundation) and the largest lung-focused charity in the country. Broader incumbent operating across all lung conditions with overlapping lung cancer support, policy advocacy, and research functions, but does not specialise in EGFR+ NSCLC.
• Macmillan Cancer Support: Major UK cancer charity providing practical, emotional, and financial support to cancer patients including those with lung cancer. Broad incumbent serving all cancer types; overlapping support services and policy advocacy but at vastly greater scale.
• Cancer Research UK: The UK's largest cancer charity, funding research, providing patient information, and lobbying on cancer policy. Broad incumbent with overlapping lung cancer research funding and information provision, but its scope spans all cancers rather than EGFR+ specifically.

Direct peers

• ALK+ UK: UK charity dedicated to ALK-positive lung cancer, the closest direct peer. Shares the same mutation-specific lung cancer charity model, co-developed the 'All You Need Is Lungs' and 'See Through the Symptoms' campaigns with EGFR+ UK, and partners on joint research with the Ruth Strauss Foundation and Open University.
• Roy Castle Lung Cancer Foundation: Major UK lung cancer charity focused on research, prevention, and patient support. Direct peer because it serves the same patient population (UK lung cancer patients and families) with overlapping services including information resources, peer support, and policy advocacy, but operates at significantly greater scale.
• Ruth Strauss Foundation: UK foundation focused on families facing lung cancer, particularly non-smokers. Direct peer and strategic campaign partner on 'All You Need Is Lungs' and 'See Through the Symptoms', with overlapping mission around lung cancer stigma and family support.
• HASAG (Mesothelioma and Lung Cancer Charity): UK charity supporting mesothelioma and lung cancer patients. Direct peer due to overlapping patient population and co-created the 'Breathe Strong' podcast with EGFR+ UK. Operates in adjacent thoracic-cancer patient support.

Regional players

• ALK Positive Lung Cancer (US): US-based advocacy organisation for ALK-positive lung cancer patients, mirroring the mutation-specific patient advocacy model in the US market. Strong structural peer in terms of approach but serves a different national healthcare system and patient base.
• EGFR Resisters: US-based patient-driven community for EGFR-mutated lung cancer patients and caregivers. Comparable mission and patient-led community model but operates primarily in the United States rather than the UK; potential cross-Atlantic learning and collaboration partner.

Others

• Lung Cancer Europe (LuCE): European umbrella organisation of lung cancer patient groups, of which EGFR+ UK became a member in August 2024. Peer in the patient-advocacy ecosystem and a channel for European-level influence rather than a directly competing charity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xbsky.app/profile/egfrpositiveuk.bsky.social
• YouTubeyoutube.com/@EGFRPositiveUK
• Facebookfacebook.com/280511092641290
• LinkedInlinkedin.com/company/egfr-positive-lung-cancer-uk

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EGFR Positive Lung Cancer UK